Osimertinib for treating EGFR mutation-positive non-small-cell lung cancer

Published on 12 Jul 2022
Last Updated on 01 Feb 2024

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Osimertinib 40 mg and 80 mg tablets for treating locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer (NSCLC) in patients whose disease has progressed on or after EGFR TKI therapy. For patients with isolated brain metastases who are clinically ineligible for re-biopsy and where T790M cannot be confirmed, osimertinib may be used until progression.

Subsidy status

Osimertinib 40 mg and 80 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.

MAF assistance does not apply to osimertinib 40 mg or 80 mg tablets adjuvant treatment of EGFR mutation-positive NSCLC after tumour resection, or for newly diagnosed locally advanced or metastatic EGFR mutation-positive NSCLC.

Clinical indications, subsidy class and MediShield Life claim limits for osimertinib are provided in the Annex.

Osimertinib for treating EGFR mutation-positive non-small-cell lung cancer (Updated 1 Feb 2024) [PDF, 199 KB]

PES Osimertinib for treating EGFR mutation-positive non-small-cell lung cancer (Published 12 July 2022) [PDF, 90 KB]